Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if the combination of HSPPC-96 and ipilimumab is
safe and effective in the treatment of advanced melanoma. HSPPC-96 is an investigational
vaccine created from tissue from the patient's tumor. The vaccine is designed to capture the
cancer's "fingerprint." Injection of the vaccine may cause the patient's immune system to
recognize and attack any cells with the specific cancer fingerprint. Ipilimumab is a drug
approved by the FDA for the treatment of metastatic melanoma that boosts immune response.